louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01411020: Target-controlled Infusion of Propofol for Induction of Pediatric Anesthesia
Official title: Target-controlled Infusion (TCI) of Propofol for Induction in Children 3 to 11 Years
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Children Under General Anesthesia
Lead sponsor: Pontificia Universidad Catolica de Chile
Sponsor class: OTHER
First posted: 2011-08-05
Enrollment: 60
Sex: ALL
Minimum age (years): 3
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine a effect-site concentration of propofol in children 3 to 11 years effective to make a induction of general anesthesia.


Eligibility criteria: Inclusion Criteria:

* obtained informed consent
* children between 3 and 11 years
* healthy
* elective surgery under general anesthesia
* no premedication

Exclusion Criteria:

* body mass index for age \> 95th percentile
* chronic or acute intake of any sedative drug
* any known adverse effect to the study drugs

Primary outcomes:
measure: dose of propofol
timeFrame: two days (duration of hospitalization)
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Hospital Clinico Universidad Catolica
state: Metropolitana
Study officials:
References:
citation: Munoz HR, Leon PJ, Fuentes RS, Echevarria GC, Cortinez LI. Prospective evaluation of the time to peak effect of propofol to target the effect site in children. Acta Anaesthesiol Scand. 2009 Aug;53(7):883-90. doi: 10.1111/j.1399-6576.2009.01995.x. Epub 2009 Jun 3.
Clinical trial NCT01742520: Neurodevelopmental Outcomes of Preterm Infants Treated for Pain Management With Repeated Doses of Sucrose 24%
Official title: Its an Interventional Study That Will Evaluate the Effect of Different Doses of Sucrose 24% on Neurodevelopmental Outcome of Preterm Infants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Development
Keywords: Preterm infant
pain
neurodevelopment
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-12-05
Enrollment: 90
Sex: ALL
Minimum age (years): 27
Maximum age (years): 33
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the effect of sucrose 24% for pain prevention on preterm infants. Our hypothesis is that repeated doses of sucrose 24%, given prior to painful procedure,do not impair neurodevelopmental outcomes of preterm infants

Detailed description: preterm infants born at 27-33 weeks gestational age at Sheba Medical Center will be recruited for this study. Prior to invasive procedure infants will be treated with pacifier and swaddling as recommended by the American Academy of Pediatrics and Canadian Pediatric Society.

Group 1.Will be treated with Sucrose 24% 0.1-0.5ml on the anterior pat of the tongue 1-3 min prior to invasive procedure.

Group 2. Similar to group 1 but breast milk or formula will replace Sucrose.

Number of invasive procedures/day will be documented

General Movements by Prechtel will be used for developmental assessment at 2,4,6 weeks after birth and at 14-16 weeks corrected age

Griffiths developmental scales (GMDS) will be used at 40 weeks, 14-16 weeks corrected age, and 3-6 month corrected age

Eligibility criteria: Inclusion Criteria:

* preterm infants born at SMC

Exclusion Criteria:

* need for intubation
* surgery
* need for sedation
* abnormal head ultrasound
* genetic abnormalities
* necrotizing enterocolitis
* other painful conditions other than routine blood exams

Primary outcomes:
measure: neurodevelopmental outcomes
timeFrame: at 6 month corrected age
Secondary outcomes:
measure: neurodevelopment
timeFrame: at 15 weeks corrected age
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Iris Morag, M.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Johnston CC, Filion F, Snider L, Majnemer A, Limperopoulos C, Walker CD, Veilleux A, Pelausa E, Cake H, Stone S, Sherrard A, Boyer K. Routine sucrose analgesia during the first week of life in neonates younger than 31 weeks' postconceptional age. Pediatrics. 2002 Sep;110(3):523-8. doi: 10.1542/peds.110.3.523.
Clinical trial NCT01175720: Clinical Comparison Between Two Surgical Techniques for the Treatment of Gingival Recessions
Official title: Clinical Comparison Between Two Surgical Techniques With Acellular Dermal Matrix Graft in the Treatment of Gingival Recessions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingival Recession
Keywords: gingival recession
acellular dermal matrix graft
root coverage
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2010-08-05
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to test a surgical technique for the treatment of gingival recessions. The hypothesis of the study is to promote greater root coverage and better healing.


Eligibility criteria: Inclusion Criteria:

* Recession defects are Miller's class I or II and do not vary more or equal than 3 mm
* Main complaint aesthetic issues or dentine hypersensitivity
* The patient must be a candidate for bilateral root coverage procedure
* Patient shows sufficient plaque control (FMPS \< 20%)
* The patient is able to comply with the study-related procedures such as exercising good oral hygiene and attending all follow-up procedures
* The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent

Exclusion Criteria:

* Smokers
* Systemic diseases
* Pregnants or lactating
* Periodontal disease
* General contraindications for dental and/or surgical treatment are present
* The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years
* The patient is taking medications or having treatments which have an effect on mucosal healing in general (e.g. steroids, large doses of anti-inflammatory drugs)

Primary outcomes:
measure: Percentage of root coverage
timeFrame: 6 months
Secondary outcomes:
measure: Keratinized Tissue
timeFrame: 6 months
Other outcomes:
Locations:
city: Ribeirão Preto
country: Brazil
facility: Faculty of Dentistry of Ribeirão Preto USP
state: São Paulo
Study officials:
affiliation: University of Sao Paulo
name: Arthur B. Novaes Júnior, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Sao Paulo
name: Lauro G. Ayub, MSD student
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ayub LG, Ramos UD, Reino DM, Grisi MF, Taba M Jr, Souza SL, Palioto DB, Novaes AB Jr. A Randomized comparative clinical study of two surgical procedures to improve root coverage with the acellular dermal matrix graft. J Clin Periodontol. 2012 Sep;39(9):871-8. doi: 10.1111/j.1600-051X.2012.01915.x. Epub 2012 Jun 19.
Clinical trial NCT02154620: Distal Radius Fractures in Patients Over 70 Years - Volar Plate or Plaster
Official title: Dorsally Displaced Distal Radius Fractures in Patients Over 70 Years - Volar Plate or Plaster - A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Distal Radius Fracture
Keywords: Distal radius fracture
wrist fracture
volar plate
surgical treatment
plaster immobilisation
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 130
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Distal radius fractures with dorsal dislocation among patients 70 years or older are randomized to conservative treatment with plaster or internal fixation with a volar plate. Thereafter they are followed at 2 weeks, 5 weeks, 3 months and 12 months with x-ray, functional scores and clinical examination.

An additional follow up at three years with X-ray, functional scores and clinical outcome will be conducted after a new written consent of continued participation in the study.

A health economy analysis will be preformed at 1, and 3 years for the participants with complete EQ5D.


Eligibility criteria: Inclusion Criteria:

* Dorsally displaced, 20 degrees or from a plane perpendicular do the diaphyseal axis, fracture.
* Low energy injury
* Patient 70 years old or older
* 72 hours or less since injury at time of diagnosis
* Patient registered in the Stockholm region
* Patient understands spoken and written swedish

Exclusion Criteria:

* Intraarticular displacement in radiocarpal joint of more than 1 mm
* Ulna fractured proximal to the base of the styloid process of ulna
* Earlier unilateral functional impairment of hand/wrist
* Injury to tendon, nerve or skin besides the fracture
* Rheumatoid arthritis or other severe systemic joint disease
* Severe psychiatric disorder, ongoing drug abuse or dementia (Pfeiffer score 5 points or less)
* Besides the wrist fracture also other big injuries, for example fracture of hip, shoulder or ankle
* Medical illness that makes general anesthesia impossible

Primary outcomes:
measure: Patient related wrist evaluation (PRWE)
timeFrame: 52 weeks
Secondary outcomes:
measure: Patient related wrist evaluation (PRWE)
timeFrame: 3 years
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Department of Orthopaedics, Stockholm South Hospital
Study officials:
affiliation: Karolinska Institutet
name: Anders Enocson, M.D, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sudow H, Severin S, Wilcke M, Saving J, Skoldenberg O, Navarro CM. Non-operative treatment or volar locking plate fixation for dorsally displaced distal radius fractures in patients over 70 years - a three year follow-up of a randomized controlled trial. BMC Musculoskelet Disord. 2022 May 12;23(1):447. doi: 10.1186/s12891-022-05394-7.
Clinical trial NCT02588820: Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection
Official title: Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection: A Pilot Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: HIV Infections
Keywords: HIV
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
Collaborators: name: Fundacion Clinic per a la Recerca Biomédica
First posted: 2015-10-28
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Pilot study to evaluate the impact of extremely early ART in the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of less than 20 days (Fiebig stages I-II) compared to patients with infection of 20-100 days (Fiebig stages III-V), to induce HIV functional cure.


Eligibility criteria: Inclusion Criteria:

* Men who have sex with men
* Male's between18 and 65 years old
* Less than 100 days of infection
* Patient stage Fiebig I to V
* Negative or Incomplete western blot with negative p31 band

Exclusion Criteria:

* P31 positive band in western blot
* Positive Delta32 CCR5 mutation, HLA-B5701 or HLA-B27 (´late' exclusion criteria)
* Active oncological disease
* Active hepatitis C virus infection

Primary outcomes:
measure: Functional cure (Proportion of patients with undetectable viral reservoir)
timeFrame: 12 months of treatment
Secondary outcomes:
measure: Proportion of patients with undetectable plasmatic HIV viral load
timeFrame: 1, 3 and 12 months post-stop antiretroviral treatment will be evaluated.
measure: Level of reduction of viral reservoir among patients treated in phase I-II Fiebig and patients treated in Fiebig stage III-V
timeFrame: 1, 3, 12 months will be measured in patients on antiretroviral treatment and at 1, 3, 12 months post-stop
measure: Level of reduction of bacterial translocation among patients treated in phase I-II Fiebig and patients treated in Fiebig stage III-V
timeFrame: 1, 3, 12 months will be measured in patients on antiretroviral treatment and at 1, 3, 12 months post-stop
measure: Level of reduction of immune activation among patients treated in phase I-II Fiebig and patients treated in Fiebig stage III-V
timeFrame: 1, 3, 12 months will be measured in patients on antiretroviral treatment and at 1, 3, 12 months post-stop
measure: Level of reduction of inflammation among patients treated in phase I-II Fiebig and patients treated in Fiebig stage III-V
timeFrame: 1, 3, 12 months will be measured in patients on antiretroviral treatment and at 1, 3, 12 months post-stop
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clínic i Provincial de Barcelona
Study officials:
References:
Clinical trial NCT04744220: Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis
Official title: Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchiectasis Adult
Keywords: Yoga Training
Quality of Life
Functional Capacity
Bronchiectasis
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2021-02-08
Enrollment: 60
Sex: ALL
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients with Bronchiectasis between the ages of 30-55

Detailed description: Investigating the effect of yoga training on functional capacity and quality of life and comparing with previous studies

Eligibility criteria: Inclusion Criteria:

* Diagnosed with bronchiectasis
* Age 30-55
* Not having a known systemic, orthopedic or neurological disease

Exclusion Criteria:

* Severe heart failure
* People who had an acute exacerbation up to three weeks ago will not be included in the study

Primary outcomes:
measure: Patient Follow-up Form
timeFrame: Baseline
Secondary outcomes:
measure: Dyspnea Assessment
timeFrame: Before and after treatment (8 week)
Other outcomes:
measure: Respiratory Function Test
timeFrame: Before and after treatment( 8 week )
measure: Quality of Life Assessment
timeFrame: Before and after treatment (8 week)
measure: Evaluation of Functional Capacity
timeFrame: Before and after treatment (8 week)
measure: Assessment of Sleep Quality
timeFrame: Before and after treatment (8 week)
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University Hospital
Study officials:
affiliation: Istanbul Medipol University Hospital
name: Salih Tan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01105520: Neurologic and Neurophysiologic Assessment of Clinical Course in Patients With Intraspinal Processes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tumor
Keywords: Intraspinal processes (tumor or vascular malformation AVM)
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2010-04-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients treated surgically for intraspinal processes

Brief summary: Patients included in the study are treated at the Klinik für Neurochirurgie USZ. The clinical course is documented at Paraplegikerzentrum Balgrist using validated diagnostic procedures (e.g. SCIM, ASIA, neurophysiology).

Study aims:

Prognostic value of clinical diagnosis and additional diagnostic procedures? Which parameters exhibit optimal prognostic power? Differences between tumor/AVM associated lesions and traumatic lesions? What can we learn for pathophysiology and treatment?

* Trial with surgical intervention


Eligibility criteria: Inclusion criteria:

* Benign intraspinal process (tumor or vascular malformation AVM)
* Primary lesion caudal of the brainstem, affecting C1
* Cognitive ability to give written informed consent

Exclusion criteria:

* Metastases, malign tumors
* Traumatic lesions
* Myelitis, polyneuropathy
* Disc prolaps

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
Clinical trial NCT01677520: Investigation of Stem Cells in Human Lipoaspirate
Official title: Investigation of Adipose-Derived Stem Cells in Human Lipoaspirate
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Cancer
Keywords: adipose-derived stem cells
viable ADSCs
apoptosis
necrosis
cryopreservation
Lead sponsor: University of Nevada, Las Vegas
Sponsor class: OTHER
First posted: 2012-09-03
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary Care Clinic

Brief summary: The overall purpose of this study is to enhance identification and isolation of ADSCs and adipocytes, to find the optimum culturing conditions to increase growth and volume of grafts, and to study the effects of cryopreservation on ADSCs and adipocytes. Fat injections are used in aesthetic surgery but tend to disassemble over time. If the investigators can enhance growth and volume of fat in culture, the investigators could use fat grafts in reconstruction of cancer and traumatic injury defects with the patients own cultured fat cells and grafts.


Eligibility criteria: Inclusion Criteria:

* All adults (18-70 yrs) who have scheduled surgical lipectomy of the hips, abdomen, or thighs are prospective subjects for this study.

Exclusion Criteria:

* Pregnant women will be excluded to protect the unborn child.

Primary outcomes:
measure: Percent of Viable ADSCs
timeFrame: Day of Surgery
Secondary outcomes:
measure: Percent of Apoptotic ADSCs
timeFrame: Day of Surgery
Other outcomes:
measure: Percent of Necrotic ADSCs
timeFrame: Day of Surgery
Locations:
city: Las Vegas
country: United States
facility: University of Nevada School of Medicine Patient Care Center
state: Nevada
Study officials:
affiliation: UNSOM
name: William A Zamboni, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: wwang@medicine.nevada.edu
name: Wei Z Wang, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00993720: Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
Official title: Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Diabetes Mellitus
Keywords: patients with type 1 diabetes mellitus
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2009-10-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.


Eligibility criteria: Inclusion Criteria:

* age 18-50y,
* BMI 18-27,
* caucasian origin,
* type 1 diabetes diagnosed between age 5 and age 40,
* no known diabetes complications or cardiovascular diseases,
* no medication known to influence glucose homeostasis,
* no pregnancy

Exclusion Criteria:

* diabetes complications,
* autonomous nerve dysfunction,
* anaemia,
* HbA1c \< 8.5% at screening,
* estimated by the investigator to be incapable of completing the trial.

Primary outcomes:
measure: insulin-dose
timeFrame: 4 weeks
Secondary outcomes:
measure: 24-hours glucose profiles with and without treatment of Victoza
timeFrame: three days
measure: risk of hypoglycemia during physical activity with and without Victoza
timeFrame: one day
measure: gastric emptying rate during hypoglycemia with and without Victoza
timeFrame: one day
measure: weight change from baseline, change in fructosamine from baseline
timeFrame: four weeks
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
References:
citation: Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.
Clinical trial NCT01508520: a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions
Official title: a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stomach Neoplasms
Keywords: early gastric cancer
stomach neoplasms
magnifying endoscopy
narrow band imaging
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2012-01-12
Enrollment: 146
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with gastric lesions suspected of early gastric malignancy

Brief summary: Magnifying endoscopy with narrow-band imaging (ME-NBI) can emphasize surface pattern and microvascular architecture of the gastric mucosa.However,the usefulness and criteria of NBI for differential diagnosis among early gastric cancers (EGC) have not been fully established.The study is based on the hypothesis:

1. ME-NBI is useful in distinguishing EGC from other gastric lesions
2. ME-NBI is useful in further differential diagnosis among EGCs.


Eligibility criteria: Inclusion Criteria:

* patients with gastric lesions which were detected by conventional screening endoscopy and suspected of early malignancy.

Exclusion Criteria:

* advanced gastric cancer or any other malignancy;
* patients under unsuitable conditions for examination or treatment, such as acute upper gastrointestinal bleeding, noncorrectable coagulopathy, severe systemic disease, etc;
* inability to provide informed consent;
* inability to provide histology of resected specimens after endoscopic treatment or surgery.

Primary outcomes:
measure: diagnosis accuracy of ME-NBI
timeFrame: in 2 weeks after ME-NBI examination
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Shanghai Ren Ji Hospital
name: Xiaobo Li, MD. Ph.D
role: PRINCIPAL_INVESTIGATOR
References: